EP Patent

EP1293210B1 — Means and method for hormonal contraception

Assigned to Pantarhei Bioscience BV · Expires 2003-11-19 · 22y expired

What this patent protects

The present invention is concerned with a kit containing a plurality of hormone units for use in a contraceptive method which consists of two alternating consecutive phases, sometimes referred to as a sequential method or sequential regimen. More particularly the present inventio…

USPTO Abstract

The present invention is concerned with a kit containing a plurality of hormone units for use in a contraceptive method which consists of two alternating consecutive phases, sometimes referred to as a sequential method or sequential regimen. More particularly the present invention relates to a kit containing a plurality of daily hormone units for use in a contraceptive method which consists of two alternating consecutive phases - an estrogenic and a progestogenic phase - of administering a sequence of said hormone units to a female of childbearing capability, the plurality of daily hormone units consisting of: a) one or more daily hormone units, for use during the estrogenic phase, containing synthetic estrogen or a combination of synthetic estrogen and biogenic estrogen in a therapeutically effective amount to inhibit ovulation and b) at least 10 daily hormone units, for use during the progestogenic phase, containing a combination of biogenic estrogen and progestogen in a therapeutically effective amount to inhibit ovulation and to transform the endometrium from a proliferative into a secretory state.

Drugs covered by this patent

Patent Metadata

Patent number
EP1293210B1
Jurisdiction
EP
Classification
Expires
2003-11-19
Drug substance claim
No
Drug product claim
No
Assignee
Pantarhei Bioscience BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.